Handelsbanken Fonder Ab Editas Medicine, Inc. Transaction History

Handelsbanken Fonder Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 03, 2021	BUY	$31.29 - $56.64 $181,482 - $328,512	5,800 Added 54.72%	16,400 $929,000
Q1 2021 Apr 29, 2021	BUY	$39.71 - $90.58 $47,652 - $108,696	1,200 Added 12.77%	10,600 $445,000
Q2 2020 Aug 13, 2020	BUY	$18.5 - $34.34 $173,900 - $322,796	9,400 New	9,400 $278,000
Q1 2019 May 10, 2019	SELL	$19.43 - $26.41 $2.62 Million - $3.57 Million	-135,000 Closed	0 $0
Q3 2018 Oct 19, 2018	BUY	$27.65 - $38.39 $414,750 - $575,850	15,000 Added 12.5%	135,000 $4.3 Million
Q2 2018 Jul 11, 2018	BUY	$31.4 - $41.01 $3.77 Million - $4.92 Million	120,000 New	120,000 $4.3 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.1M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.